Stay updated on PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Sign up to get notified when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.

Latest updates to the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page revision label was updated from v3.2.0 to v3.3.2 in the footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedDeletion of the government funding status notice that could indicate potential delays; this does not alter the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check35 days agoChange DetectedNo additions or deletions detected on the page. The observed changes appear to be routine metadata updates (e.g., last update timestamps) rather than substantive edits to study content.SummaryDifference0.5%

- Check64 days agoChange DetectedThe page now includes a government-funding lapse notice and a new v3.2.0 update, replacing the old v3.1.0 tag.SummaryDifference4%

- Check71 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

- Check85 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed, representing a minor UI change.SummaryDifference0.2%

Stay in the know with updates to PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.